Sample Size Determination for Phase II Clinical Trials Based on Bayesian Decision Theory
From MaRDI portal
Publication:4665959
DOI10.2307/2534014zbMath1058.62656WikidataQ47291830 ScholiaQ47291830MaRDI QIDQ4665959
Publication date: 11 April 2005
Published in: Biometrics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.2307/2534014
optimal stopping; cost-benefit analysis; backwards induction; multistage design; group sequential procedure
62P10: Applications of statistics to biology and medical sciences; meta analysis
62C10: Bayesian problems; characterization of Bayes procedures
62L05: Sequential statistical design
Related Items
Decision Theoretic Designs for Phase II Clinical Trials with Multiple Outcomes, Bayesian designs with frequentist and Bayesian error rate considerations, A Bayesian Decision Approach for Sample Size Determination in Phase II Trials, Decision-Theoretic Designs for Pre-Phase II Screening Trials in Oncology, Decision-Theoretic Designs for Phase II Clinical Trials Allowing for Competing Studies, Bayesian approach to determine the number of subsequent users of a new treatment